Drug Profile
CH 4051
Alternative Names: CH-4051; L-CH-1504Latest Information Update: 27 Jun 2014
Price :
$50
*
At a glance
- Originator University of South Alabama
- Developer Lundbeck A/S
- Class Anti-inflammatories
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
- 31 May 2012 Chelsea Therapeutics completes the phase II MOTION trial in Rheumatoid arthritis (treatment-resistant) in the US, Bulgaria and the Czech Republic (NCT01116141)
- 31 May 2012 Suspended - Phase-I for Autoimmune disorders (in volunteers) in Netherlands (PO)